Virpax Pharmaceuticals Azioni (OTC: VRPX)

Ultime notizie per Virpax Pharmaceuticals (OTC:VRPX) Azioni

Virpax Pharmaceuticals

Virpax Pharmaceuticals Inc is a preclinical stage biopharmaceutical company. The company is focused on developing pharmaceutical product candidates for pain management. Its product portfolio includes Topical metered-dose spray; Liposomal in Hydrogel encapsulation; and Enkephalin Intranasal spray.

VIRPAX PHARMS INC by Virpax Pharmaceuticals, Inc.

Virpax Pharmaceuticals Inc

Cantor Fitzgerald analyst Troy Jensen initiates coverage on D-Wave Quantum (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/QBTS#NYSE">QBTS</a>) with a Overweight rating and announces Price Target of $20.

News

Price Target

Initiation

Analyst Ratings

QBTS

Cantor Fitzgerald Initiates Coverage On D-Wave Quantum with Overweight Rating, Announces Price Target of $20

Cantor Fitzgerald analyst Troy Jensen initiates coverage on Rigetti Computing (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGTI#NASDAQ">RGTI</a>) with a Overweight rating and announces Price Target of $15.

RGTI

Cantor Fitzgerald Initiates Coverage On Rigetti Computing with Overweight Rating, Announces Price Target of $15

<h3>Gainers</h3>
<table>
<thead>
<tr>
<th>Symbol</th>
<th>Name</th>
<th align="right">Price</th>
<th align="right">Change ($)</th>
<th align="right">Change (%)</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLE#NYSE">XLE</a>)</td>
<td>SPDR Select Sector Fund - Energy Select Sector</td>
<td align="right">86.2000</td>
<td align="right">0.74</td>
<td align="right">0.86</td>
<td>179.2K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLY#NYSE">XLY</a>)</td>
<td>SPDR Select Sector Fund - Consumer Discretionary</td>
<td align="right">219.9201</td>
<td align="right">1.66</td>
<td align="right">0.76</td>
<td>30.8K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLB#NYSE">XLB</a>)</td>
<td>Materials Select Sector SPDR</td>
<td align="right">90.4600</td>
<td align="right">0.38</td>
<td align="right">0.42</td>
<td>710</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLF#NYSE">XLF</a>)</td>
<td>SPDR Select Sector Fund - Financial</td>
<td align="right">52.8095</td>
<td align="right">0.15</td>
<td align="right">0.28</td>
<td>146.8K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLP#NYSE">XLP</a>)</td>
<td>SPDR Select Sector Fund - Consumer Staples</td>
<td align="right">82.1100</td>
<td align="right">0.13</td>
<td align="right">0.15</td>
<td>12.4K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLU#NYSE">XLU</a>)</td>
<td>SPDR Select Sector Fund - Utilities</td>
<td align="right">82.0200</td>
<td align="right">0.08</td>
<td align="right">0.09</td>
<td>12.3K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLI#NYSE">XLI</a>)</td>
<td>SPDR Select Sector Fund - Industrial</td>
<td align="right">148.0500</td>
<td align="right">0.04</td>
<td align="right">0.02</td>
<td>3.1K</td>
</tr>
</tbody>
</table>
<h3>Losers</h3>
<table>
<thead>
<tr>
<th>Symbol</th>
<th>Name</th>
<th align="right">Price</th>
<th align="right">Change ($)</th>
<th align="right">Change (%)</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLK#NYSE">XLK</a>)</td>
<td>SPDR Select Sector Fund - Technology</td>
<td align="right">250.03</td>
<td align="right">-0.94</td>
<td align="right">-0.38</td>
<td>54.7K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLV#NYSE">XLV</a>)</td>
<td>SPDR Select Sector Fund - Health Care</td>
<td align="right">136.23</td>
<td align="right">-0.48</td>
<td align="right">-0.36</td>
<td>9.0K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLRE#NYSE">XLRE</a>)</td>
<td>Real Estate Select Sector SPDR Fund (The)</td>
<td align="right">41.67</td>
<td align="right">-0.03</td>
<td align="right">-0.08</td>
<td>37.1K</td>
</tr>
<tr>
<td>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLC#NYSE">XLC</a>)</td>
<td>The Communication Services Select Sector SPDR Fund</td>
<td align="right">107.75</td>
<td align="right">-0.01</td>
<td align="right">-0.01</td>
<td>653</td>
</tr>
</tbody>
</table>
<a href="https://pro.benzinga.com/?utm_source=insights">Pulled from Benzinga Pro data</a> this sector movers alerts can help traders understand macro-level market trends. Traders often look for sector movers to provide high-level analysis on which sectors are over- or under-performing to make better investing decisions on exchange traded funds (ETFs) or individual tickers in those sectors. 
For more information on sector movers, <a href="https://www.benzinga.com/movers">click here</a>.

Sector ETFs

Pre-Market Outlook

Movers

ETFs

XLRE

Select Sector SPDR-Consumer Discretionary

Leading And Lagging Sectors For July 2, 2025

Cantor Fitzgerald analyst Troy Jensen initiates coverage on Quantum Computing (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QUBT#NASDAQ">QUBT</a>) with a Neutral rating and announces Price Target of $15.

QUBT

Cantor Fitzgerald Initiates Coverage On Quantum Computing with Neutral Rating, Announces Price Target of $15

1.3 million patients are hospitalized annually in the U.S. from acute heart failure and it is the #1 cause of hospitalization in patients &gt;65 years old
If istaroxime is approved in the US for acute heart failure, this patent would provide protection to 2039
WARRINGTON, Pa., July 02, 2025 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. ("Windtree" or the "Company") (NasdaqCM: WINT), a diversified company focused on revenue generation in multiple growing industries is pleased to announce that the United States Patent and Trademark Office has issued an istaroxime patent for the United States - application number 18/150,870 directed to "ISTAROXIME-CONTAINING INTRAVENOUS FORMULATION FOR THE TREATMENT OF ACUTE HEART FAILURE."
Acute heart failure, or AHF, impacts millions of patients globally and istaroxime has previously completed two positive Phase 2 AHF studies and two positive early cardiogenic shock studies caused by acute heart failure.

Biotech

General

WINT

Windtree Therapeutics Secures U.S. Patent For Istaroxime IV Formulation In Acute Heart Failure, Providing Protection Through 2039

<ul>
<li>Partnership to acquire 2022-built DP2 Suezmax shuttle tanker Daqing Knutsen</li>
<li>Sale &amp; leaseback of Tove Knutsen expected to release approximately $32 million of proceeds</li>
<li>Partnership is establishing a $10 million common unit buyback program</li>
</ul>
KNOT Offshore Partners LP (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KNOP#NYSE">KNOP</a>) ("The Partnership") today provided a strategic and operational update on a number of developments involving fleet expansion, chartering, refinancing, and a common unit buyback program.
In addition to the updates related to ongoing operations and additional detail provided later in this announcement, key developments include the following:
<ul>
<li>The outstanding debt of the Tove Knutsen is expected to be refinanced by means of a sale &amp; leaseback transaction, which would generate approximately $32 million of proceeds;</li>
<li>The Partnership has agreed to acquire the 2022-built DP2 shuttle tanker Daqing Knutsen (the "Acquisition") from Knutsen NYK Offshore Tankers AS ("KNOT"). The purchase price is $95 million, less $70.5 million of outstanding indebtedness, plus $0.3 million of capitalized fees related to the credit facility secured by the Daqing Knutsen and subject to customary post-closing adjustments for working capital. The vessel is on time charter to PetroChina in Brazil through July 2027. As a term of the Acquisition, KNOT has guaranteed the hire rate for the vessel until 2032 on the same basis as if PetroChina had exercised its option through such date;</li>
<li>In recognition of the value proposition represented by the prevailing market valuation of the Partnership's common units, KNOP is establishing a $10 million common unit buyback program; and</li>
<li>The Partnership's quarterly distribution for 2Q 2025 has been maintained at $0.026 per common unit.</li>
</ul>

KNOP

KNOT Offshore Partners To Acquire 2022-Built DP2 Shuttle Tanker Daqing Knutsen From KNOT For $95M Less Debt; Net Consideration ~$24.8M

Cineverse Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CNVS#NASDAQ">CNVS</a>), a global streaming technology and entertainment company, today announced its inclusion in multiple FTSE Russell indexes, effective June 29 and June 30, 2025, as part of the annual reconstitution of the Russell U.S. Indexes.
Cineverse has been added to the following indexes:
<ul>
<li>Russell 3000E&#xAE; Index (Effective June 30, 2025)</li>
<li>Russell 3000E&#xAE; Growth Index (Effective June 30, 2025)</li>
<li>Russell 3000E&#xAE; Value Index (Effective June 29, 2025)</li>
<li>Russell Microcap&#xAE; Index (Effective June 30, 2025)</li>
<li>Russell Microcap&#xAE; Growth Index (Effective June 30, 2025)</li>
<li>Russell Microcap&#xAE; Value Index (Effective June 30, 2025)</li>
</ul>
Inclusion in these indexes expands Cineverse's visibility across a wide range of institutional investors and index-tracking funds. The Russell indexes are broadly used by asset managers and institutional investors as benchmarks for passive and active investment strategies.

CNVS

Cineverse Added To Multiple Russell 3000E And Russell Microcap Indexes

Cantor Fitzgerald analyst Troy Jensen initiates coverage on IonQ (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IONQ#NYSE">IONQ</a>) with a Overweight rating and announces Price Target of $45.

IONQ

Cantor Fitzgerald Initiates Coverage On IonQ with Overweight Rating, Announces Price Target of $45

B of A Securities analyst Andrew Obin maintains Emerson Electric (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EMR#NYSE">EMR</a>) with a Buy and raises the price target from $130 to $155.

B of A Securities Maintains Buy on Emerson Electric, Raises Price Target to $155

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul class="wp-block-list">
<li>Guggenheim cut TEGNA Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TGNA#NYSE">TGNA</a>) price target from $22 to $21. Guggenheim analyst Curry Baker maintained a Buy rating. TEGNA shares closed at $16.93 on Tuesday. See how other analysts view <a href="https://www.benzinga.com/quote/TGNA/analyst-ratings">this stock</a>.</li>
<li>Stephens &amp; Co. raised the price target for MSC Industrial Direct Co., Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MSM#NYSE">MSM</a>) from $85 to $90. Stephens &amp; Co. analyst Tommy Moll maintained an Equal-Weight rating. MSC Industrial Direct shares closed at $90.32 on Tuesday. See how other analysts <a href="https://www.benzinga.com/quote/MSM/analyst-ratings">view this stock</a>.</li>
<li>UBS raised Altria Group, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MO#NYSE">MO</a>) price target from $47 to $59. UBS analyst Faham Baig upgraded the stock from Sell to Neutral. Altria Group shares closed at $58.14 on Tuesday. See how other analysts <a href="https://www.benzinga.com/quote/MO/analyst-ratings">view this stock</a>.</li>
<li>JP Morgan cut the price target for Centene Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNC#NYSE">CNC</a>) from $75 to $48. JP Morgan analyst John Stansel downgraded the stock from Overweight to Neutral. Centene shares closed at $56.65 on Tuesday. <a href="https://www.benzinga.com/quote/CNC/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Jefferies raised the price target for Ross Stores, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ROST#NASDAQ">ROST</a>) from $135 to $150. Jefferies analyst Corey Tarlowe upgraded the stock from Hold to Buy. Ross Stores shares closed at $129.97 on Tuesday. <a href="https://www.benzinga.com/quote/ROST/analyst-ratings">See how other analysts view this stock.</a></li>
<li>JMP Securities raised Carvana Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVNA#NYSE">CVNA</a>) price target from $275 to $440. JMP Securities analyst Nicholas Jones maintained a Market Outperform rating. Carvana shares settled at $338.26 on Tuesday. <a href="https://www.benzinga.com/quote/CVNA/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Needham increased Axos Financial, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AX#NYSE">AX</a>) price target from $88 to $92. Needham analyst Kyle Peterson maintained a Buy rating. Axos Financial shares closed at $78.32 on Tuesday. <a href="https://www.benzinga.com/quote/MSFT/analyst-ratings">See how other analysts view this stock.</a></li>
<li>HC Wainwright &amp; Co. increased Enliven Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ELVN#NASDAQ">ELVN</a>) price target from $40 to $48. HC Wainwright &amp; Co. analyst Robert Burns maintained a Buy rating. Enliven Therapeutics shares closed at $19.65 on Tuesday.  <a href="https://www.benzinga.com/quote/MSFT/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Baird boosted the price target for Chipotle Mexican Grill, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CMG#NYSE">CMG</a>) from $58 to $62. Baird analyst David Tarantino maintained an Outperform rating. Chipotle shares settled at $58.24 on Tuesday. <a href="https://www.benzinga.com/quote/MSFT/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Baird increased Meta Platforms, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>) price target from $635 to $740. Baird analyst Colin Sebastian maintained an Outperform rating. Meta shares closed at $719.22 on Tuesday. <a href="https://www.benzinga.com/quote/MSFT/analyst-ratings">See how other analysts view this stock</a>.</li>
</ul>
Considering buying META stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><a href="https://www.benzinga.com/quote/meta/analyst-ratings"><img loading="lazy" decoding="async" width="1024" height="611" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/02090254/image-28-1024x611.png" alt="" class="wp-image-970387" style="width:602px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/02090254/image-28-1024x611.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/02090254/image-28-300x179.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/02090254/image-28-768x458.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/02090254/image-28.png 1090w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>
Read This Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/dividends/25/07/46216643/wall-streets-most-accurate-analysts-give-their-take-on-3-financial-stocks-delivering-high-dividend-yields-4">Wall Street&#8217;s Most Accurate Analysts Give Their Take On 3 Financial Stocks Delivering High-Dividend Yields</a> </li>
</ul>
Photo via Shutterstock

Markets

Trading Ideas

CVNA

ELVN

ROST

TGNA

Meta To Rally Around 3%? Here Are 10 Top Analyst Forecasts For Wednesday

WIIM

TSLA

Tesla shares are trading higher after the company reported Q2 total production of 410,244 vehicles and total deliveries of 384,122 vehicles.

Some moments demand intensity, and few sports deliver it quite like Professional Bull Riders (PBR). That's why FRE&#xAE; Nicotine Pouches is stepping into the arena as an official partner of Unleash The Beast, the sport's premier individual series. The multi-year deal is <a href="https://www.globenewswire.com/Tracker?data=ysZrAVfjQvQSIxeR9s9NMqPeIlKI2P_ZBHTvRWpVlhxJYoVA2eDtf-oTlivqWeASeTUY46OulW-9yAZeUUa2yA==">FRE's </a>biggest sports sponsorship ever, and it's all about bringing high-energy moments to fans.
A Partnership Rooted in Boldness
"Professional Bull Riding delivers the most exciting 8 seconds in sports, and we're thrilled to be part of that energy through our title sponsorship of the Unleash The Beast," said Connor Smith, VP of Marketing for FRE. "PBR's viewership has been steadily rising, and the sport is selling out iconic venues coast to coast – that's the kind of passionate, engaged audience that aligns perfectly with FRE's innovative approach to nicotine. Our PBR partnership represents more than just sponsorship; it's about connecting with fans who appreciate authenticity, seizing the moment, and pushing boundaries."
Passion Meets Power: FRE x PBR Connect with Fans in a Whole New Way at Cowboys Stadium
To kick things off, FRE made waves at Kid Rock's Rock N Rodeo and PBR World Finals - Championship from May 16–18 at AT&amp;T Stadium, the home of the Dallas Cowboys. This event marked FRE's debut with PBR, bringing Western sports fans face-to-face with an innovative nicotine experience. FRE's spirit is now woven into the competition itself. At the Championship, PBR introduced the "FRE Challenge Button," a new feature allowing bull riders to request a judges' review for a second chance at an official score. <a href="https://www.globenewswire.com/Tracker?data=HBdN3iiUbFAtAh1K8ktfgLAQIgeOlHkYrZ8OF2sc4-i7UPJcLQY3r_e_IDqqjQnR7fqPoRdcNLIzmG4dOttAwA==">FRE </a>isn't just a sponsor—it's part of the action.
"We're thrilled to welcome FRE to the PBR family," said Josh Baker, Chief Revenue Officer, PBR. "Their support brings fresh energy to the sport while also directly contributing to creating more opportunities and putting more money in the pockets of our athletes. Non-endemic partnerships like this are vital to our continued growth and success."
During Kid Rock's Rock N Rodeo, the Low Riders team showcased the FRE logo as they participated in thrilling activities such as breakaway roping and barrel racing.
Looking Ahead
With the 2025 PBR Unleash The Beast season kicking off soon, expect even bigger activations, deeper brand integration, and new ways for fans to engage with FRE.
"Our coming out party at Championship weekend was just the beginning of a long-term partnership with PBR, and we are excited to work together, creating innovative activations and deeper brand integrations,"&nbsp;Smith said. "Fans can expect to hear more from FRE as we continue to engage with the Western sports audience. This is the start of something big for our brand, and we are thrilled to be part of the PBR family."

TKO Group's Professional Bull Riders Signs Multi-Year Title Sponsorship With FRE Nicotine Pouches

Plumas Bancorp ("Plumas") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLBC#NASDAQ">PLBC</a>) announced today the completion of its acquisition of Cornerstone Community Bancorp ("Cornerstone"), the holding company for Cornerstone Community Bank, effective July 1, 2025. On the same day, Cornerstone Community Bank merged with and into Plumas's subsidiary, Plumas Bank. The transaction was previously announced on January 28, 2025.
Under the terms of the merger agreement between Plumas and Cornerstone, each issued and outstanding share of common stock of Cornerstone was converted into the right to receive a combination of 0.6608 shares of Plumas common stock and $9.75 in cash. The value of the total deal consideration was approximately $61.3 million, based on the closing price of Plumas common stock of $44.46 per share on June 30, 2025.

PLBC

Cornerstone Community Bank Merges With And Into Plumas's Subsidiary, Plumas Bank, In $61.3M Deal

Macro Notification

Tesla Q2 Total Production 410,244, Total Deliveries 384,122

Neo-Concept International Group Holdings Limited Announces It Has Regained Compliance With Nasdaq

Baird analyst Colin Sebastian maintains Wayfair (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/W#NYSE">W</a>) with a Neutral and raises the price target from $33 to $52.

Baird Maintains Neutral on Wayfair, Raises Price Target to $52

The U.S. labor market is flashing a rare warning sign after private sector payrolls fell in June for the first time in over two years, raising concerns about the economy&#8217;s health and increasing bets on Federal <a href="https://www.benzinga.com/topic/interest-rates">Reserve interest rate cuts.</a>
Private employers cut 33,000 jobs last month, according to the ADP National Employment Report released Thursday. 
That's a sharp drop from the downwardly revised 29,000 gain in May and far below economist forecasts for a 95,000 increase. 
The last time this data showed a monthly contraction was in March 2023, coinciding with the collapse of Silicon Valley Bank and Signature Bank, which triggered a brief banking crisis.
The ADP report precedes the more closely watched U.S. government jobs report from the Bureau of Labor Statistics, due on Thursday. Economists expect nonfarm payrolls to slow from 139,000 in May to 110,000 in June.
<h2 class="wp-block-heading">Where Job Losses Hit Hardest In June</h2>
The losses were concentrated in service-providing sectors, which collectively shed 66,000 jobs. Within that group, professional and business services lost 56,000 jobs, while education and health services dropped 52,000. Financial activities cut 14,000 positions.
There were modest gains in leisure and hospitality (+32,000), trade, transportation and utilities (+14,000), and information (+5,000). Meanwhile, goods-producing industries added 32,000 jobs, driven largely by manufacturing.
"Though layoffs continue to be rare, a hesitancy to hire and a reluctance to replace departing workers led to job losses last month," said Nela Richardson, chief economist at ADP. "Still, the slowdown in hiring has yet to disrupt pay growth."
&#8220;Though layoffs continue to be rare, a hesitancy to hire and a reluctance to replace departing workers led to job losses last month. Still, the slowdown in hiring has yet to disrupt pay growth,&#8221; Richardson added.
Despite the hiring freeze, wage growth held firm. Year-over-year pay for job stayers increased 4.4%, while those who changed jobs saw an average 6.8% boost in salaries, indicating underlying labor market tightness remains.
<h2 class="wp-block-heading">Market Reactions: Traders Add Rate Cut Bets</h2>
Markets immediately responded to the surprise job contraction by ramping up bets on Federal Reserve rate cuts. The odds of a July rate cut increased to 25%, up from 20% the previous day.
Traders now fully price in a rate cut by September and expect another 25-basis-point reduction by December.
Despite the weak labor print, U.S. equity futures remained steady. Contracts on the S&amp;P 500 hovered around 6,200 points in premarket trading in New York.
Gold futures – as tracked by the SPDR Gold Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GLD#NYSE">GLD</a>) – spiked on the back of increased rate cut expectations. Bullion rose to $3,350 per ounce as investors sought safety amid labor market uncertainties.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/equities/25/07/46215165/us-stocks-likely-to-open-higher-sp-500-sees-average-gain-of-6-1-in-2nd-half-expert-says">US Stocks Likely To Open Higher: S&amp;P 500 Sees &#8216;Average Gain Of 6.1%&#8217; In 2nd Half, Expert Says </a></li>
</ul>
Photo: Shutterstock

Analyst Color

Macro Economic Events

Commodities

Econ #s

Economics

Labor Market Flashes Red Signal—And The Last Time This Happened It Didn't End Well

Stock Split

CYCC

Cyclacel Pharmaceuticals Announces 1-for-15 Reverse Stock Split, Effective Jul. 7

Cantor Fitzgerald analyst Sarah James maintains Centene (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNC#NYSE">CNC</a>) with a Overweight and lowers the price target from $90 to $65.

Comments

Virpax Pharmaceuticals

Notizie

Ultime notizie per Virpax Pharmaceuticals (OTC:VRPX) Azioni

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO